Showing 2181-2190 of 5696 results for "".
- Oculus Debuts Dual Testing Functionality on Easyfield VR for Enhanced Visual Field Assessmenthttps://modernod.com/news/oculus-debuts-dual-testing-functionality-on-easyfield-vr-for-enhanced-visual-field-assessment/2482416/Oculus has announced the debut of dual testing functionality on its Oculus Easyfield VR, which allows for both Frequency Doubling Perimetry (FDP) and Standard Automated Perimetry (SAP). The integration of Frequency Doubling Perimetry into the Easyfield VR allows for the potent
- Rayner Launches First AI-Designed Spiral IOL, the RayOne Galaxyhttps://modernod.com/news/rayner-announces-launch-of-rayone-galaxy-first-ai-designed-spiral-iol/2482411/Rayner announced its plans to launch the RayOne Galaxy and Galaxy Toric, which the company is calling the world’s first IOL designed with the aid of artificial intelligence. The IOLs will be unveiled at the European Society of Cataract and Refractive Surgeons (
- Ocutech Announces Release of SideSight Ultrasonic Sensor Device for Homonymous Hemianopiahttps://modernod.com/news/ocutech-announces-limited-release-of-sidesight-ultrasonic-sensor-device-for-homonymous-hemianopia/2482405/Ocutech announced the limited first release of its new ultrasonic sensor device, the SideSight. Developed in collaboration with experts in electrical, software, and mechanical engineering, Ocutech says the SideSight is designed to assist individuals who have experienced loss of side vision, a con
- Opus Genetics Receives FDA Rare Pediatric Disease Designation for Gene Therapy OPGx-LCA5https://modernod.com/news/opus-genetics-receives-fda-rare-pediatric-disease-designation-for-gene-therapy-opgx-lca5/2482403/Opus Genetics announced that the FDA has granted rare pediatric disease (RPD) designation for its ocular gene therapy, OPGx-LCA5. This therapy is designed to treat patients with Leber congenital amaurosis (LCA) type 5, a rare inherited retinal disease caused by biallelic mutations in th
- Atsena Therapeutics Secures FDA Rare Pediatric Disease Designation for XLRS Gene Therapyhttps://modernod.com/news/atsena-therapeutics-secures-fda-rare-pediatric-disease-designation-for-gene-therapy-targeting-x-linked-retinoschisis/2482398/The FDA has granted rare pediatric disease (RPD) designation for Atsena Therapeutics' gene therapy pruduct candidate ATSN-201, which is being examined to treat X-linked retinoschisis (XLRS). XLRS is a rare genetic disorder that leads to vision loss primarily in males.
- Contact Lens Institute Opens Nominations for Second Annual Culture Awardshttps://modernod.com/news/contact-lens-institute-opens-nominations-for-second-annual-culture-awards/2482394/The Contact Lens Institute (CLI) has announced that nominations for the second annual CLI Culture Awards are now open, with submissions being accepted through October 1, 2024. This program aims to recognize eye care professionals who are committed to fostering a positive culture around contact le
- Study Examines Effectiveness of Injection of Retinal Progenitor Cells (RPCs) in Treating Photoreceptor Degenerationhttps://modernod.com/news/study-examines-effectiveness-of-injection-of-retinal-progenitor-cells-rpcs-in-treating-photoreceptor-degeneration/2482387/A preclinical study demonstrates the effectiveness of intravitreal injection of retinal progenitor cells (RPCs) (jCell) in treating photoreceptor degeneration. The research, from the Gavin Herbert Eye Institute and Sue & Bill Gross Stem Cell Research Center at the University of
- Novaliq Receives Positive CHMP Opinion for Vevizye in Dry Eye Diseasehttps://modernod.com/news/novaliq-receives-positive-chmp-opinion-for-vevizye-in-dry-eye-disease/2482383/Novaliq announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending the granting of a marketing authorization in the European Union for dry eye drug Vevizye. Vevizye is intended for the treatment
- First Beyeonics One Augmented Reality Surgical Microscope Installed at Deep Blue Retinahttps://modernod.com/news/first-beyeonics-one-augmented-reality-surgical-microscope-installed-at-deep-blue-retina/2482377/The first Beyeonics One surgical microscope for retinal surgery was installed at Southaven, Mississippi-based Deep Blue Retina. The system will be installed at Desoto Surgery Center, part of the Surgery Partners network. The Beyeonics One system offers precision and
- Nicox Announces Recruitment of Last Patient in US in Denali Phase 3 Trial of NCX 470https://modernod.com/news/nicox-announces-recruitment-of-last-patient-in-us-in-denali-phase-3-trial-of-ncx-470/2482375/Nicox announced the recruitment and randomization of the last patient in the United States in its Denali phase 3 trial of NCX 470. The Denali trial is evaluating NCX 470 safety and efficacy in patients with open-angle glaucoma or ocular hypertension. Ac